Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccines01:21

Vaccines

53
Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the...
53
Vaccinations01:51

Vaccinations

54.6K
Overview
54.6K
Vaccine Production01:23

Vaccine Production

75
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
75
Cancer Vaccines01:30

Cancer Vaccines

1.4K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.4K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.4K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.4K
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

77
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
77

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk and protective factors for cognitive decline in older adults from a nationally representative sample in India: Results from the LASI-DAD.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Health and economic burdens of emerging infectious diseases in the USA, US territories and globally.

BMJ global health·2026
Same author

Vision loss, disability and multimorbidity among older people in Andhra Pradesh and Telangana in South India: the longitudinal eye health, ageing and disability study (LEADS) - study protocol.

BMJ public health·2026
Same author

Health Service Leaders' Perspectives on Type 1 Diabetes Models of Care for Children and Young Adults in Australia: A Mixed-Methods Study.

Journal of diabetes research·2026
Same author

Estimating the economic burden of lower respiratory infections in China from 2020 to 2040: a health-augmented macroeconomic modelling study.

The Lancet regional health. Western Pacific·2026
Same author

The full value of mRNA seasonal influenza and endemic-stage COVID-19 combination vaccines: a taxonomy.

Journal of medical economics·2026
Same journal

Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study.

Vaccine·2026
Same journal

Safety and immunogenicity of a reduced, homologous booster dose of the BNT162b2 mRNA COVID-19 vaccine: a single blind, randomized, non-inferiority follow-up trial.

Vaccine·2026
Same journal

Vaccination policies for healthcare personnel in Europe, 2026.

Vaccine·2026
Same journal

A historical overview of the anti-vaccine movement and its public health implications.

Vaccine·2026
Same journal

Vaccine strategies and development before and during the 1968 H3N2 influenza pandemic.

Vaccine·2026
Same journal

Influence of correlated vaccination behaviors on estimates of COVID-19 vaccine effectiveness in older adults - VISION network, October 2023 - March 2024.

Vaccine·2026
See all related articles

Related Experiment Video

Updated: Apr 11, 2026

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

1.7K

Vaccines: from valuation to resource allocation.

David E Bloom1, Guruprasad Madhavan2

  • 1Harvard T.H. Chan School of Public Health, Boston, MA, United States.

Vaccine
|May 30, 2015
PubMed
Summary
This summary is machine-generated.

Valuing vaccines requires better methods to measure their benefits. This helps in making informed health policy decisions for immunization programs and resource allocation.

Keywords:
Data collectionResource allocationStrategic planning tools

More Related Videos

Rapid, Seamless Generation of Recombinant Poxviruses using Host Range and Visual Selection
09:25

Rapid, Seamless Generation of Recombinant Poxviruses using Host Range and Visual Selection

Published on: May 24, 2020

5.9K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.4K

Related Experiment Videos

Last Updated: Apr 11, 2026

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

1.7K
Rapid, Seamless Generation of Recombinant Poxviruses using Host Range and Visual Selection
09:25

Rapid, Seamless Generation of Recombinant Poxviruses using Host Range and Visual Selection

Published on: May 24, 2020

5.9K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.4K

Area of Science:

  • Public Health
  • Health Economics
  • Vaccinology

Background:

  • Assessing the full value of vaccines is complex.
  • Current valuation methods face challenges in conceptualization and measurement.
  • Effective use of valuation data in health policy is an opportunity.

Purpose of the Study:

  • To review challenges and opportunities in vaccine valuation.
  • To explore the strategic use of valuation data in health policy.
  • To highlight the need for improved data and tools for vaccine assessment.

Main Methods:

  • Literature review on vaccine valuation.
  • Analysis of conceptual and measurement challenges.
  • Discussion of opportunities for policy integration.

Main Results:

  • Valuation of vaccines is hindered by conceptual and measurement difficulties.
  • Strategic use of valuation data can inform national immunization plans and resource allocation.
  • Enhanced data collection and planning tools are crucial for transparently assessing vaccine trade-offs.

Conclusions:

  • Clarifying vaccine benefits at individual, family, and community levels is essential.
  • Improved valuation supports better cost-benefit comparisons.
  • Systematic assessment of vaccine attributes in diverse contexts is needed for optimal decision-making.